PubMed Daily Triage Digest — 2026-07-31
Run: attempt1-20260731T090000Z | Schema: v1.3 | Status: complete
Window: 2026-07-30 → 2026-07-31 UTC | Articles output: 29 (9 HIGH, 17 STANDARD, 3 LOW)
🔴 FLAG_FAST_TRACK (Score ≥ 8, Primary Data)
1. Phase 3 RCT: Low-dose ruxolitinib dramatically reduces acute GVHD in haploidentical HCT
PMID: 42532067 | Score: 9/10 | Journal: Lancet Haematol 2026 Aug;13(8):e533–e544
Topic: Sentinel | DOI: 10.1016/S2352-3026(26)00167-5
In 206 patients undergoing myeloablative haploidentical HSCT, replacing MMF with low-dose ruxolitinib (5 mg BID through day 60) within ATG+CNI+methotrexate backbone reduced grade II–IV acute GVHD by day 100 from 36.9% → 6.8% (SHR 0.15, 95% CI 0.07–0.34; p<0.0001), with manageable toxicity and no treatment-related deaths.
Why it matters: ~5-fold reduction in GVHD with a JAK inhibitor represents a paradigm shift for haploidentical transplant. Immediate implications for transplant programs considering standard-of-care updates. Phase 3 level evidence in Lancet Haematol.
2. Phase 2 RCT: Dose-intensified vs standard [177Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA)
PMID: 42532645 | Score: 8/10 | Journal: J Nucl Med 2026 Jul 30
Topic: Sentinel | DOI: 10.2967/jnumed.126.272714
OPTIMAL-PSMA is a Phase 2 open-label RCT comparing dose-intensified vs standard regimens of lutetium PSMA-597 in metastatic castration-resistant prostate cancer — directly addressing optimal dosing for PSMA radioligand therapy in the post-PSMA-617 approval era.
Why it matters: PSMA-targeted radioligand therapy is one of the fastest-growing treatment modalities in prostate cancer. Dosing optimization data from a randomized trial fills a critical gap in clinical practice.
🟠 HIGH Priority (Score 7–9)
3. Largest-ever HCT registry study in r/r Hodgkin lymphoma (19,498 patients, EBMT)
PMID: 42532066 | Score: 9/10 | Journal: Lancet Haematol 2026 Aug;13(8):e519–e532
Topic: Hematologic Malignancies | DOI: 10.1016/S2352-3026(26)00169-9
EBMT registry analysis across 600+ centers/53 countries: auto-HCT 2-year OS improved from 85% → 93% and PFS from 63% → 73% over 2010–2022 (n=15,648). Allo-HCT 2-year PFS improved from 44% → 62% (n=3,850). Disease status at transplantation remains the dominant predictor.
Why it matters: Defines modern HCT outcomes in Hodgkin lymphoma in the novel-agent era. The temporal improvement data sets the new benchmark for auto- and allo-HCT and will be foundational for future trial comparator arms.
4. ctDNA WGS predicts recurrence in Stage IA NSCLC with 16.7-month lead time
PMID: 42532206 | Score: 8/10 | Journal: J Mol Diagn 2026 Jul 30
Topic: Early Cancer Detection | DOI: 10.1016/j.jmoldx.2026.07.003
Tumor-informed whole-genome ctDNA sequencing in 42 Stage IA NSCLC patients achieved 0.75 sensitivity and 0.83 specificity for recurrence detection, with a median 16.7-month lead time over clinical/imaging recurrence. Also distinguished second primary from true recurrence.
Why it matters: Stage IA NSCLC has no validated ctDNA surveillance approach; this is the earliest clinical stage where liquid biopsy MRD monitoring has been demonstrated, providing a window for adjuvant intervention.
5. MD Anderson validates 2-day TAT plasma liquid biopsy NGS (cfTNA)
PMID: 42532207 | Score: 8/10 | Journal: J Mol Diagn 2026 Jul 30
Topic: Early Cancer Detection | DOI: 10.1016/j.jmoldx.2026.07.004
MD Anderson validation of Oncomine cfTNA on Genexus Sequencer: >99% analytical sensitivity/specificity for SNVs/indels in 107 clinical plasma samples; 72.2% sensitivity for fusions; average TAT ≤2 days vs typical 5–10 days for standard liquid biopsy assays.
Why it matters: TAT is a major bottleneck in liquid biopsy clinical utility. A validated rapid-turnaround assay from a leading cancer center enables same-week treatment decision-making.
6. Ultrasensitive ctDNA improves prognostication in TNBC post-neoadjuvant (ESMO Open)
PMID: 42531804 | Score: 8/10 | Journal: ESMO Open 2026;11(8):108334
Topic: Early Cancer Detection | DOI: 10.1016/j.esmoop.2026.108334
Multicenter French study demonstrating ultrasensitive ctDNA detection post-NAT improves risk stratification in TNBC beyond pathological complete response status — the current prognostic standard. High-risk patients identifiable early for adjuvant therapy escalation.
Why it matters: TNBC has ~40% rate of residual disease after NAT with high relapse risk; ctDNA-based risk stratification could guide adjuvant therapy decisions (capecitabine, olaparib, pembrolizumab escalation/de-escalation).
7. Regional gilteritinib practice variation significantly impacts outcomes in FLT3-ITD AML post-HCT
PMID: 42532509 | Score: 7/10 | Journal: Blood Adv 2026 Jul 30
Topic: Hematologic Malignancies | DOI: 10.1182/bloodadvances.2026020327
International multicenter registry analysis (Johns Hopkins, Mayo, MSKCC, international) demonstrates that regional differences in post-HCT gilteritinib prescribing patterns (dose, timing, duration) significantly affect outcomes in FLT3-ITD AML patients on maintenance therapy.
Why it matters: Post-HCT gilteritinib is FDA-approved standard-of-care but implementation is heterogeneous. Practice-level evidence identifying high-impact variables is immediately actionable for BMT programs.
8. Real-world AI tumor cell content quantification outperforms pathologist visual estimation
PMID: 42532480 | Score: 7/10 | Journal: Lab Invest 2026 Jul 30
Topic: AI/ML Clinical Diagnostics | DOI: 10.1016/j.labinv.2026.106157
300-specimen validation at University Hospital Zurich: AI digital quantification (AIM-TC/PathAI) showed Rs=0.63 correlation with molecular ground truth vs Rs=0.38 for visual pathologist quantification. 98.5% sensitivity, 99% specificity at single-cell level across 5 cancer types. Pre-analytical factors (specimen type, cautery artifacts) identified as key implementation challenges.
Why it matters: Tumor cell content is the gating quality metric for all molecular profiling; pathologist variability is a known source of NGS failures. AI-assisted quantification is now validated in routine clinical workflow.
9. Real-world finerenone effectiveness and safety in T2DM+CKD (MEDFINE-RWD, Spain)
PMID: 42533276 | Score: 7/10 | Journal: Diabetes Obes Metab 2026 Jul 30
Topic: GLP-1/SGLT2/Cardiometabolic | DOI: 10.1111/dom.71160
First Spanish multicenter real-world study of finerenone (non-steroidal MRA) in T2DM+CKD, complementing phase 3 FIDELIO/FIGARO data with routine clinical practice evidence for this cardiorenal protective drug.
10. Sustained efficacy of IV plasminogen concentrate in pediatric Type 1 PLG deficiency
PMID: 42528055 | Score: 7/10 | Journal: Pediatr Blood Cancer 2026 Jul 29
Topic: Rare Diseases | DOI: 10.1002/1545-5017.70454
Multicenter longitudinal analysis (Indiana HTC, Great Ormond Street, Vanderbilt, others) of Ryplazim (IV plasminogen concentrate) in pediatric Type 1 plasminogen deficiency — an ultra-rare disorder causing ligneous conjunctivitis and mucosal pseudomembrane disease — providing dosing optimization data essential for this small patient community.
🟡 STANDARD Priority (Score 4–6) — Selected Highlights
| PMID | Title | Journal | Score | Topic |
|---|---|---|---|---|
| 42530947 | ctDNA in Head & Neck Cancer: AHNS Review | JAMA Otolaryngol Head Neck Surg | 6 | Early Cancer Detection |
| 42533093 | BRCA1/2 population screening Latvia pilot study | Eur J Hum Genet | 6 | Precision Oncology |
| 42533114 | Dual-targeting PROTAC (IKKβ/NR4A1) for AML | Oncogene | 5 | Hematologic Malignancies |
| 42532782 | Deep learning vs manual MTC grading on FNA (negative result) | J Am Soc Cytopathol | 5 | AI/ML Diagnostics |
| 42532746 | CAR-T vs chemo in pancreatic cancer organoids | Pancreatology | 5 | Novel Therapeutics |
| 42533264 | GLP-1 RA spending/affordability US 2013–2023 | J Gen Intern Med | 5 | Cardiometabolic |
| 42533048 | SGLT2i + loop diuretics fluid dynamics in CKD | Hypertens Res | 5 | Cardiometabolic |
| 42532407 | Cisplatin-induced ecDNA drives chemoresistance in gastric cancer | J Adv Res | 5 | Precision Oncology |
| 42533123 | Secreted protein signaling inference method (Nat Methods) | Nat Methods | 5 | Novel Therapeutics |
| 42533201 | RAG in radiology: scoping review (Stanford co-authored) | J Imaging Inform Med | 4 | AI/ML Diagnostics |
| 42533229 | SGLT2i and asymptomatic bacteriuria in T2DM | Infection | 4 | Cardiometabolic |
| 42532972 | Neuralgic amyotrophy after BCMA CAR-T (novel safety signal) | Muscle Nerve | 4 | Novel Therapeutics |
| 42532761 | Thyroid irAEs from ICIs in NSCLC (multi-method study) | Clin Ther | 4 | Novel Therapeutics |
| 42532989 | Longitudinal aging connectome resource (open dataset) | Sci Data | 4 | Aging/Longevity |
| 42530141 | Clinical pharmacology modeling for rare disease drug dev | J Clin Pharmacol | 4 | Rare Diseases |
| 42533220 | App-based lifestyle modification after PCI: multicenter RCT | Cardiovasc Interv Ther | 4 | Sentinel |
🔵 LOW Priority (Score ≤ 3)
| PMID | Title | Topic | Note |
|---|---|---|---|
| 42529457 | dNLR/NLR/NMLR markers in emphysematous pyelonephritis | CBC/ML Hematology | Only T2 hit; peripherally relevant |
| 42531151 | X-Linked Dystonia-Parkinsonism in Filipino men (scoping review) | Rare Diseases | Ultra-rare; scoping review only |
| 42533025 | Mortality trends in arrhythmia+CVD in older adults (US) | Aging/Longevity | Descriptive epidemiology |
📊 Coverage Summary
| Topic | Searched | Returned | Reviewed | HIGH | Notes |
|---|---|---|---|---|---|
| Hematologic malignancies | ✓ | 65 | 15 | 2 | |
| CBC/ML hematology | ✓ | 1 | 1 | 0 | Sparse day |
| Early cancer detection | ✓ | 21 | 15 | 3 | Best topic today |
| AI/ML clinical diagnostics | ✓ | 26 | 10 | 1 | |
| Precision oncology/genomics | ✓ | 25 | 10 | 0 | Overlap with T3 |
| Novel therapeutics | ✓ | 117 | 10 | 0 | Sentinel captured key RCT |
| GLP-1/SGLT2/cardiometabolic | ✓ | 66 | 5 | 1 | |
| Aging/longevity (humans[MeSH]) | ✓ | 23 | 5 | 0 | |
| Rare diseases | ✓ | 5 | 5 | 1 | |
| Sentinel | ✓ | 39 | 10 | 2 | Two RCTs captured |
📝 Run Notes
- Top signal today: Phase 3 RCT of low-dose ruxolitinib for GvHD prophylaxis (PMID 42532067) is the highest-impact finding — a ~5-fold GVHD reduction in haploidentical HCT will likely change transplant practice guidelines.
- ctDNA cluster: Three independent ctDNA/liquid biopsy articles indexed today (Stage IA NSCLC WGS MRD, rapid MD Anderson NGS validation, TNBC post-NAT prognostication) — strong signal in the liquid biopsy space.
- CBC/ML hematology topic: Sparse hit day (1 record only); NLR-based study is marginally on-topic. Recommend query broadening for future runs if T2 continues to produce <3 records.
- Novel therapeutics (T6): 117 total returned but reviewed only 10; most matched keyword but were not oncology-relevant primary endpoints. Sentinel topic captured the most clinically impactful RCT (ruxolitinib GvHD Phase 3).
- esummary truncation: PMID 42533114 (Oncogene, PROTAC AML) had esummary truncated; title-based classification applied with low confidence — score capped conservatively per schema rules.
- Attempt: 1 of 3 | Validator will promote files at:
/root/.openclaw/workspace/reports/pubmed/2026-07-31-triage.jsonand-digest.md
Generated: 2026-07-31T09:09Z | Pipeline: Pulse PubMed Triage v1.3 | Model: anthropic/claude-sonnet-4-6